Advertisement

Topics

ASIT Biotech Announces the Initiation of a Phase 2a Clinical Study of Its Second Product Candidate hdm-ASIT+TM for House Dust Mite Rhinitis

13:00 EDT 22 Sep 2016 | Biotech 365

BRUSSELS–(BUSINESS WIRE)–Regulatory News: ASIT biotech (Paris:ASIT – BE0974289218) (BSE:ASIT), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, is pleased to announce that its phase 2a trial … Continue reading

Cet article ASIT Biotech Announces the Initiation of a Phase 2a Clinical Study of Its Second Product Candidate hdm-ASIT+TM for House Dust Mite Rhinitis est apparu en premier sur Biotech 365.

Original Article: ASIT Biotech Announces the Initiation of a Phase 2a Clinical Study of Its Second Product Candidate hdm-ASIT+TM for House Dust Mite Rhinitis

NEXT ARTICLE

More From BioPortfolio on "ASIT Biotech Announces the Initiation of a Phase 2a Clinical Study of Its Second Product Candidate hdm-ASIT+TM for House Dust Mite Rhinitis"

Quick Search
Advertisement